Skip to main content

Radioactive plaque

It crossed my mind some time ago to write a blog post called ‘Ten good things about having a child with eye cancer.’ Ten silver linings of an undeniably dark cloud. I’m not actually sure I could get to ten, but one of the things that would be up there is how much of Asa’s childhood we've had the opportunity to see (more than most parents, whose children can be safely packed away to a childminder or nursery while parents get on with making a living). Another would be the awareness that the fight against the disease has given us of the gifts of life and sight, which many people can take for granted.

The downsides are all too clear, of course. The misery of having poisons infused into your child’s bloodstream; the fear we felt, during chemo, of some infection snatching Asa’s life away; the repeated exams under general anaesthetic (more than 45 so far, since diagnosis); the sore, red eyes after exams, and the rigmarole of coaxing him to let us put stinging drops in them to control the swelling. The struggle to find the right words to explain to him, as he grows in awareness, why it is we submit him to these things. And the challenge of relating what we’re going through to others, who don’t know this disease (Why should they?) -- and why it is that, after more than 3 years of treatment, we still can’t give a simple answer to the question, “What's the prognosis?”

Asa at 4 months (approx 6 months before diagnosis), and today

A friend remarked recently that given all we’ve been through, we must have built up a certain toughness. Indeed we have; but there are still some areas of vulnerability. Sometimes small things can knock us sideways, like the difference between a four-week and five-week interval between EUAs. Usually the interval has been three or four weeks, and while you might think a longer interval would be better (More time away from hospital!), the extra week can feel like a long time, and your mind turns to wondering whether the tumours might be growing out of control as the clock ticks.

Another thing that tests us is coming to terms with new kinds of treatment. On the principle of “better the devil you know”, we come to feel comfortable with treatments Asa’s received in the past (particularly cryo and laser therapy, which he’s had lots of), and we get anxious about new ones. But when a relapse occurs that can't be treated effectively with methods that the doctors have used in the past, it’s inevitable that we have to consider new options.

Asa receiving an award from the Childhood Eye Cancer Trust, in recognition of his bravery. Hackney Farm, March 2015. 

Last month Asa had a relapse in a part of his eye that's dangerously close to the ciliary body -- a structure that can serve as a conduit for tumour cells to travel outside the eye. Left unchecked, this could lead to the cancer colonising new parts of the body, and becoming a threat not just to his sight but to his life.

The treatment that the doctors have recommended on this occasion is radioactive plaque -- a piece of radioactive material inserted into the eye (stitched onto the surface of the eyeball) and left there for about a day and a half, to do its work. This approach was suggested to us a few months ago, as something that might be necessary if certain areas of activity didn’t respond to cryo. But only recently did the doctors make a forceful case for doing it now.

For almost as long as we've known about radiotherapy as a treatment for eye cancer, we've been scared of it. Back in 2013, a recommendation that Asa undergo external beam radiotherapy (EBRT) prompted us to look at the medical literature on this treatment, its rates of success and complications. What did we find? EBRT can be said quite unequivocally to be effective in treating tumours in the eye. But it’s also associated with increased risks of later life cancers -- particularly sarcomas in areas of the body that are exposed to collateral damage from the radiation beam, such as the bridge of the nose, or parts of the eye socket. These “secondary cancers” are very difficult to treat, and can be fatal. Which puts EBRT in the category of treatments that can cure the disease but risk killing the patient in the process (or at least reducing lifespan considerably).

Radioactive plaque definitely does not belong in this category. The radioactive substance that’s been recommended for Asa (ruthenium isotope 106) has a very sharp tail-off, and shouldn’t penetrate beyond a few millimeters into the eye. The radioactive material is enclosed in a metal case (thicker on one side than the other, so as to shield neighbouring structures), and is applied flush with the area of the eye that needs treating. All this serves to minimize exposure of surrounding tissue to radiation.

We've come around, in the last few weeks, to accepting that this is the best treatment available. But it’s still stressful. We ruminate on whether the treatment will work. Will the tumours in the right eye finally stop growing? Will there be side effects beyond the inevitable swelling and soreness? In September, when Asa starts primary school, will he still have the vision he has now? We can’t know the answers to these questions. We just have to wait and see, and hope and pray. 

This much we do know. Tomorrow morning Asa will go into the operating theatre at Birmingham Children's Hospital. He’ll sit on my lap or his mum’s to receive the anaesthetic gas through a face-mask, and we’ll tell him a bedtime story as he drifts off. We’ll likely be reunited with him around noon, by which time he’ll have had the plaque inserted, and from then on he’ll be confined to a side-room for the rest of the day and night, and for most of the following day, until they take the plaque out again in the evening. In the interim, we have to make the best we can of the time. Fill it with as much humour and distraction -- and joy, and love -- as we can.


  1. Hey Uncle Jed, (not sure if that's what I call you, never really needed to know before, haha)

    Just went through my e-mails and saw a link to this blog sent from my Grandma Kay. Read through every blog entry from the start. What a roller-coaster of a story. Asa seems like such a wonderful boy. I very much hope to meet him, one day. Your family has such a story and the strength that both you and Aunt Selam show through these entries is incredible. I'm so relieved to hear how drastically Asa's condition has improved over the course of the different treatments and am so very hopeful about this latest treatment.

    Just wanted to show my support from across the pond. Wishing your family the best,


Post a Comment

Popular posts from this blog

Relapse. Birthday.

Wednesday'sExamination Under Anaesthetic yielded some unexpected news.
In Asa's left eye, which had been stable since the end of primary chemo in June, there were 4 or 5 new tumours, and one previously treated tumour that was growing slowly. There were also some new seeds.
In his right eye, moreover, the tumours that had earlier responded well to Melphalan had started to relapse.
These areas are at the front of the eye -- as the doctor put it, "almost where the retina finishes."
And the seeds that were there last time had not responded to the cryotherapy.

Treatment options
When Selam picked Asa up from the recovery room, both of his eyes were red and swollen from cryotherapy.
Cryo is a stop-gap measure: Since too much of it can cause retinal detachment, this approach doesn't hold much promise for controlling the tumour growth in the long term.
The area of tumour activity is also too wide for the more gentle kinds of radiotherapy -- such as radiation delivered through a …

Mixed results

Last Wednesday Asa was put to sleep and underwent an eye exam under anaesthetic. 
The first since the beginning of the new chemo, the exam showed that the drugs have had a "partial effect."

In Asa's left eye, the tumours responded well to the chemo. 
But in the right eye, there's been a slight increase in tumour activity.
And in the left eye there's a cataract developing.
A mixed bag
This was not what we'd hoped to hear.
We had reason to expect that the TVD (topotecan-vincristine-doxorubicin) combination would lead to shrinkage of the tumours in both eyes. 
And the appearance of a cataract -- a clouding of the lens -- at this stage is unusual: puzzling to the doctors as well as us.
While cataracts can be removed through surgery, cutting into the eye when there are active tumours inside is not advisable. So treatment for the cataract itself will have to wait until the tumours are stable.
The main risk in the near future is that the cataract may make it difficult to moni…

Hard questions

One morning recently, when we were trying to get Asa to put on his socks, he asked us, seemingly out of nowhere: “What does it have in it, my right eye?” It was clear he wasn’t in discomfort; it wasn’t that he had a piece of grit in there. He pointed up at his eye with his index finger.
“Well, it’s got jelly in it,” I said. “And a retina, and a lens. And lots of other things we didn’t know about two years ago.” “And what does it have in it, my left eye? Does it have a lens?” “No, your left eye doesn’t have a lens.” “What happened to it, the lens?” “The doctor took it out, because the eye was poorly.” “Was the lens poorly?” “It had gotten --” “Cloudy,” Selam offered. “Yes, it had gotten all cloudy, and you couldn't see well through it. So he took it out.” “Who took it out?”  “The doctor took it out.” “It doesn’t have any lens.” “No. That’s why you have to wear glasses sometimes, so you can see better. And that’s why Mummy patches your right eye sometimes. Because we want you to see as well as …